Medtronic and Philips Partner to Innovate in Lung Cancer Management

In a collective effort to improve the management of patients with lung nodules, Medtronic plc (NYSE: MDT) and Royal Philips (NYSE: PHG) have entered into a business relationship to develop and commercialize the LungGPS(TM) Patient Management Platform.
As quoted in the press release:

Lung cancer remains the number one cancer killer in the world, accounting for more cancer deaths than breast, colon and prostate cancer combined¹. In its early stages, lung cancer presents few, if any, symptoms. Lung nodules, also referred to as “spots” or “shadows” on the lung, are usually benign. But when found early, nodules can be continuously monitored for growth, which is a sign that the nodule could become cancerous.

Click here to read the full press release.